Metropolis Healthcare Limited announced its financial results for the second quarter and first half of fiscal year 2027. The company reported a 16% year-over-year increase in revenue for Q2 FY27, reaching INR 497 crore. For the first half of FY27, revenue grew by 16% YoY to INR 947 crore. EBITDA and PAT also demonstrated strong growth across both periods, driven by volume increases and operational efficiencies.
Metropolis Healthcare Q2 and H1 FY27 Financial Highlights
Metropolis Healthcare Limited has released its financial performance for the quarter and half-year ended September 30, 2026. The company demonstrated robust growth, outperforming guidance and showcasing strong operational momentum.
Q2 FY27 Performance
In the second quarter of fiscal year 2027 (Q2 FY27), Metropolis Healthcare recorded Revenue from Operations of INR 496.8 crore, a substantial 15.8% increase compared to INR 429.2 crore in Q2 FY26. Reported EBITDA stood at INR 134.9 crore, up 23.9% YoY, with an EBITDA Margin of 27.2%, an improvement of 180 bps. Profit After Tax (PAT) was INR 75.5 crore, marking a significant 42.7% increase from the previous year, resulting in a PAT Margin of 15.2%.
H1 FY27 Performance
For the first half of fiscal year 2027 (H1 FY27), the company’s Revenue from Operations reached INR 947.0 crore, reflecting a 16.2% year-over-year growth. Reported EBITDA for H1 FY27 was INR 248.2 crore, up 25.3% YoY, with an EBITDA Margin of 26.2%, an improvement of 190 bps. Profit After Tax (PAT) for H1 FY27 stood at INR 132.4 crore, a notable 34.9% increase from INR 98.1 crore in H1 FY26, with a PAT Margin of 14.0%.
Key Drivers of Growth
The company attributed its strong performance to sustained demand momentum and increased throughput from its expanded Lab & Center network. Growth in Q2 FY27 was driven by volume and a favorable mix across channels and regions, with broad-based performance in TruHealth & Specialty Diagnostics. EBITDA growth was fueled by operating leverage, automation, and continued process efficiencies. The mid-teen revenue growth was delivered despite no price hikes, indicating strong underlying demand and volume-led growth.
Infrastructure and Reach
Metropolis continues to build a scalable and productive network. The Laboratory Network has grown to 213 labs by H1FY27, adding 52 labs over the last 5 years. The Service Network has expanded to 5,119 service points, with 490 centers added in FY26 alone. The company has a presence in approximately 750 towns, up from 300 in FY23, with revenue contribution diversified across geographies and city tiers.
Strategic Pillars
Metropolis 3.0, the company’s strategy for its next phase of profitable, science-led growth, focuses on strengthening the core, expanding into adjacencies, and building shareholder value. Key pillars include Leading with Technology, Differentiating Scientifically, Consistent Profitable Growth, and Brand Promise, all underpinned by Strong Governance.
Corporate Social Responsibility
The company is actively involved in various CSR initiatives, including Adolescent Reproductive Sexual Health (ARSH), MedEngage for nurturing young medical talent, and Preventive Healthcare programs aimed at community well-being.
Leadership Team
Metropolis is led by a dynamic leadership team, with Dr. Sushil Shah as Founder & Non-Executive Non-Independent Director and Ameera Shah as Promoter & Executive Chairperson, supported by a professional management team.
Recent Accolades
Metropolis Healthcare has received several awards and accolades in recent periods, recognizing its excellence in precision diagnostics, personalized healthcare, social impact, and leadership in the diagnostics sector.
Source: BSE
